XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
The Business Financial Information & Liquidity (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
Sep. 14, 2016
USD ($)
clinical_trial_subject
$ / shares
shares
Jul. 28, 2016
$ / shares
Mar. 11, 2016
USD ($)
Sep. 30, 2016
USD ($)
$ / shares
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
shares
Mar. 10, 2016
$ / shares
Dec. 31, 2015
$ / shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Share Price | $ / shares                 $ 7.05  
Reverse Stock Split, Conversion Ratio   0.1                
Common Stock, Par Value | $ / shares   $ 0.001   $ 0.001     $ 0.001     $ 0.001
Shares Issued, Price Per Share | $ / shares $ 4.72                  
Hitachi Chemical Co., LTD [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Proceeds From Licensing Agreements     $ 25,000   $ 1,250 $ 22,500        
Unrecorded Unconditional Purchase Obligation, Maximum Quantity     15,000              
PCT Allendale, LLC [Member] | Hitachi Chemical Co., LTD [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Proceeds From Licensing Agreements     $ 10,000              
Oxford Finance LLC [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Repayments of Debt     $ 7,000 $ 3,000            
RD Purchase Agreement [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Stock Issued During Period, Shares, New Issues | shares 847,458                  
Proceeds from Issuance of Common Stock $ 4,000                  
Private Purchase Agreement [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Stock Issued During Period, Shares, New Issues | shares             1,398,305      
Proceeds from Issuance of Common Stock             $ 6,600      
Purchase Commitment, Maximum Amount Committed, Shares | shares 4,449,153                  
Proceeds from Issuance of Common Stock, Initial Closing $ 12,600                  
Proceeds from Issuance of Common Stock, Second Closing $ 8,400                  
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing | clinical_trial_subject 70                  
Private Purchase Agreement [Member] | Subsequent Event [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Stock Issued During Period, Shares, New Issues | shares               1,271,186    
Proceeds from Issuance of Common Stock               $ 6,000